Anna Stanhewicz, PhD

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Anna Stanhewicz, PhD sits in the top decile of US sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count).

14 total trials 10 currently recruiting 3 completed early-phase tilt top decile by trial count

Anna Stanhewicz, PhD: 14 sponsored US clinical trials, 10 recruiting.

Anna Stanhewicz, PhD sponsors 14 registered US clinical trials on ClinicalTrials.gov, 10 of them currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Gestational Diabetes, with 4 trials.

Top-decile sponsor footprint

Anna Stanhewicz, PhD ranks in the top decile of sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

14 total, page 1 of 1

RECRUITING Phase 1

The Impact of Gestational Diabetes Mellitus on Cerebral Blood Flow and Cerebrovascular Function After Pregnancy

NCT06911372
RECRUITING Early Phase 1

Vascular Effects of High-Salt After Preeclampsia

NCT06749418
RECRUITING Early Phase 1

Role of ET-1, Physical Activity, and Sedentary Behavior in Microvascular Dysfunction Following GDM

NCT06547619
RECRUITING Early Phase 1

Metformin for the Treatment of Microvascular Dysfunction After Gestational Diabetes

NCT05917587
RECRUITING Early Phase 1

Sex Differences in the Vascular Effects of E-cigarette Use

NCT06159608
RECRUITING Early Phase 1

Daily Aspirin Treatment After Preeclampsia

NCT06168461
RECRUITING Early Phase 1

Role of NADPH Oxidase in Microvascular Dysfunction Following GDM

NCT05946798
RECRUITING Early Phase 1

Oxidative Stress in Microvascular Dysfunction Following Gestational Diabetes

NCT05946785
RECRUITING Early Phase 1

Sensitivity of Angiotensin II Type II Receptors in Women Following Preeclampsia

NCT05937841
RECRUITING Early Phase 1

Prenatal Aspirin and Postpartum Vascular Function

NCT05653973
ACTIVE NOT RECRUITING Early Phase 1

MR and Inflammation After Preeclampsia

NCT07345845
COMPLETED Early Phase 1

Balance of Angiotensin II Receptors in Vessel Function After Preeclampsia

NCT06157580
COMPLETED Early Phase 1

Sex Differences in the Dilatory Response of Compound 21

NCT05576155
COMPLETED Early Phase 1

Losartan for Improved Vascular Endothelial Function After Preeclampsia

NCT04632589

Phase Distribution

PhaseTrial count
Phase 1 14

Therapeutic Areas

Gestational Diabetes 4
Preeclampsia 4
Preeclampsia Postpartum 3
Vascular Endothelial Function 2
Sex Differences 1
Uncomplicated Pregnancy 1
Postpartum Women 1
Microvascular Function 1
Gestational Diabetes Mellitus (GDM) 1
E-cigarette Use 1

What is open in the Anna Stanhewicz, PhD pipeline

10 recruiting of 14 indexed (71% open); 3 completed (21%).

Phase mix: 0 late (III/IV) vs 14 early (I/II) (early-phase heavy).

Top condition: Gestational Diabetes (4 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Anna Stanhewicz, PhD: open-pipeline peers nationwide

Peers matched on 14 registered trials and 71% open enrollment, not the therapeutic-area sidebar.

Anna Stanhewicz, PhD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 681012141618 0%20%40%60%80% Total trials Recruiting share Anna Stanhewicz, PhD3-C Institute for Social DevelopmentAbbott Medical OpticsAbbott RDx CardiometabolicAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAGlenn J. HannaSenthil SadhasivamCorEvitasRevolution Medicines
Anna Stanhewicz, PhD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Anna Stanhewicz, PhD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 14 trials (± recruiting share)

Sponsors near 71% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Anna Stanhewicz, PhD page

14 registered trials is a research-attention snapshot, not an endorsement of Anna Stanhewicz, PhD or any single study.

  • 10 of Anna Stanhewicz, PhD's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Gestational Diabetes is the condition Anna Stanhewicz, PhD studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Gestational Diabetes trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Anna Stanhewicz, PhD pipeline card: 14 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.